Derivative of Bardoxolone Methyl, dh404, in an Inverse Dose-Dependent Manner Lessens Diabetes-Associated Atherosclerosis and Improves Diabetic Kidney Disease
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Derivative of Bardoxolone Methyl, dh404, in an Inverse Dose-Dependent Manner Lessens Diabetes-Associated Atherosclerosis and Improves Diabetic Kidney Disease
Authors
Keywords
-
Journal
DIABETES
Volume 63, Issue 9, Pages 3091-3103
Publisher
American Diabetes Association
Online
2014-04-17
DOI
10.2337/db13-1743
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Rationale and Trial Design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: The Occurrence of Renal Events (BEACON)
- (2013) Dick de Zeeuw et al. AMERICAN JOURNAL OF NEPHROLOGY
- Reactive Oxygen Species in Inflammation and Tissue Injury
- (2013) Manish Mittal et al. ANTIOXIDANTS & REDOX SIGNALING
- The absence of macrophage Nrf2 promotes early atherogenesis
- (2013) Anna-Kaisa Ruotsalainen et al. CARDIOVASCULAR RESEARCH
- Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease
- (2013) Stacey Ruiz et al. KIDNEY INTERNATIONAL
- Epidemiology of Diabetic Kidney Disease
- (2013) Anne T. Reutens MEDICAL CLINICS OF NORTH AMERICA
- Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease
- (2013) Dick de Zeeuw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Myeloid Deletion of Nuclear Factor Erythroid 2−Related Factor 2 Increases Atherosclerosis and Liver Injury
- (2012) Alan R. Collins et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Prevention of Diabetic Complications by Activation of Nrf2: Diabetic Cardiomyopathy and Nephropathy
- (2012) Bing Li et al. Experimental Diabetes Research
- Nrf2 in bone marrow-derived cells positively contributes to the advanced stage of atherosclerotic plaque formation
- (2012) Nobuhiko Harada et al. FREE RADICAL BIOLOGY AND MEDICINE
- Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study
- (2012) Marcello Tonelli et al. LANCET
- Effects of Stimulation of Soluble Guanylate Cyclase on Diabetic Nephropathy in Diabetic eNOS Knockout Mice on Top of Angiotensin II Receptor Blockade
- (2012) Ina M. Ott et al. PLoS One
- Effect of Bardoxolone Methyl on Kidney Function in Patients with T2D and Stage 3b–4 CKD
- (2011) Pablo E. Pergola et al. AMERICAN JOURNAL OF NEPHROLOGY
- Adaptive induction of NF-E2-related factor-2-driven antioxidant genes in endothelial cells in response to hyperglycemia
- (2011) Zoltan Ungvari et al. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
- Dedifferentiation of Immortalized Human Podocytes in Response to Transforming Growth Factor- : A Model for Diabetic Podocytopathy
- (2011) M. Herman-Edelstein et al. DIABETES
- Nrf2 Activators as Attractive Therapeutics for Diabetic Nephropathy: FIG. 1.
- (2011) Judy B. de Haan DIABETES
- Therapeutic Potential of Nrf2 Activators in Streptozotocin-Induced Diabetic Nephropathy
- (2011) Hongting Zheng et al. DIABETES
- Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes
- (2011) Pablo E. Pergola et al. NEW ENGLAND JOURNAL OF MEDICINE
- NF-E2–Related Factor 2 Promotes Atherosclerosis by Effects on Plasma Lipoproteins and Cholesterol Transport That Overshadow Antioxidant Protection
- (2010) Berenice Barajas et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Antiatherosclerotic and Renoprotective Effects of Ebselen in the Diabetic Apolipoprotein E/GPx1-Double Knockout Mouse
- (2010) P. Chew et al. DIABETES
- The Protective Role of Nrf2 in Streptozotocin-Induced Diabetic Nephropathy
- (2010) T. Jiang et al. DIABETES
- Caffeic acid phenethyl ester-mediated Nrf2 activation and IκB kinase inhibition are involved in NFκB inhibitory effect: Structural analysis for NFκB inhibition
- (2010) Youna Lee et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Transcriptional Regulation of Renal Cytoprotective Genes by Nrf2 and Its Potential Use as a Therapeutic Target to Mitigate Cisplatin-Induced Nephrotoxicity
- (2010) L. M. Aleksunes et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- The Nrf2 System as a Potential Target for the Development of Indirect Antioxidants
- (2010) Kyeong-Ah Jung et al. MOLECULES
- Site-Specific Antiatherogenic Effect of the Antioxidant Ebselen in the Diabetic Apolipoprotein E–Deficient Mouse
- (2009) Phyllis Chew et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Dihydro-CDDO-Trifluoroethyl Amide (dh404), a Novel Nrf2 Activator, Suppresses Oxidative Stress in Cardiomyocytes
- (2009) Tomonaga Ichikawa et al. PLoS One
- Activation of NF-E2-Related Factor-2 Reverses Biochemical Dysfunction of Endothelial Cells Induced by Hyperglycemia Linked to Vascular Disease
- (2008) M. Xue et al. DIABETES
- Nrf1 and Nrf2 Play Distinct Roles in Activation of Antioxidant Response Element-dependent Genes
- (2008) Makiko Ohtsuji et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The Antioxidant Defense System Keap1-Nrf2 Comprises a Multiple Sensing Mechanism for Responding to a Wide Range of Chemical Compounds
- (2008) M. Kobayashi et al. MOLECULAR AND CELLULAR BIOLOGY
- Disruption of Nrf2, a Key Inducer of Antioxidant Defenses, Attenuates ApoE-Mediated Atherosclerosis in Mice
- (2008) Thomas E. Sussan et al. PLoS One
- Coordinated induction of Nrf2 target genes protects against iron nitrilotriacetate (FeNTA)-induced nephrotoxicity
- (2008) Y TANAKA et al. TOXICOLOGY AND APPLIED PHARMACOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started